o4 antibody, anti-human/mouse/rat  (Miltenyi Biotec)

Journal: Bioactive Materials

Article Title: Injection site dictates the immune response to a biodegradable polymer and corresponding collagen regeneration

doi: 10.1016/j.bioactmat.2026.04.004

Figure Lengend Snippet: ID tissue exhibits higher densities of fibroblasts, macrophages, and microvessels compared to SC tissue. Immunofluorescence analysis comparing the expression of Vimentin (a fibroblast marker), CD68 (a macrophage marker), and CD31 (an endothelial cell marker) in ID and SC tissues. For each group, n = 3; data represent mean ± s.d.; ∗P < 0.05 and ∗∗P < 0.01.

Article Snippet: After antigen retrieval and blocking, sections were incubated overnight at 4 °C with primary antibodies targeting vimentin, CD68 (ABclonal, A20803), CD31 (R&D SYSTEMS, AF3628), HMGB1 (Cell Signaling Technology, 3935), HSP70 (ABclonal, A23457), NF-κB p65 (ABclonal, A19653), CD206 (Cell Signaling Technology, 24595), and FAPα (ABclonal, A23789 ).

Techniques: Immunofluorescence, Expressing, Marker

Journal: iScience

Article Title: cGAS/STING sensing in dendritic cells discriminates between daptomycin sensitive and resistant Staphylococcus aureus clinical isolates

doi: 10.1016/j.isci.2026.115854

Figure Lengend Snippet: TLR2 is required for MutuDC sensing of, but not internalization of MRSA (A) Relative pHrodo labeled MRSA internalization by MutuDC over 4 h following stimulation with DapS A8819 (light blue symbols) or DapR A8817 (dark blue symbols), or media alone (white squares). Prior to stimulation, MutuDC were pre-treated for 1 h with TLR2 blocking antibody (clone T2.5; triangles with dashed lines) or media alone (circles with filled lines). Relative MRSA internalization by each DC subset is expressed as the gMFI of pHrodo. Results show the mean and (SD) of duplicates from one experiment, representative of two independent experiments. (B) Cytokine secretion (pg/mL) by MutuDC stimulated with TLR2 ligand peptidoglycan of S. aureus (PGN-SA) (10 μg/mL) or (C) DapS (A8819; light blue) or DapR (A8817; dark blue) MRSA (MOI of 10) for 18 h. MutuDC were first pre-treated with either TLR2 blocking antibody (dot-filled bars) or media alone (filled bars) as in A, or an isotype control (clone 163D3, empty bars) at 1 μg/mL. Results pooled from four (B) or three (C) independent experiments and expressed as the mean ± SEM, with each symbol (circle, square, and directional triangles) representing paired experimental replicates ( n = 3). Statistical significance determined using paired t test and reported as indicated by an ∗ when p ≤ 0.05. (D) Expression of surface activation markers by MutuDC stimulated with DapS A8819 MRSA. DC were pre-treated with TLR2 blocking antibody (black trace), isotype control (dashed red trace), and media alone (light blue shaded). Unstained control sample is shown for each marker (black dashed trace). Data shown from one experiment, representative of three independent experiments.

Article Snippet: mAB mTLR2- anti-mouse/human TLR2 , InvivoGen , Cat# mab-mtlr2; RRID: AB_763722.

Techniques: Labeling, Blocking Assay, Control, Expressing, Activation Assay, Marker

Journal: iScience

Article Title: Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity

doi: 10.1016/j.isci.2026.116022

Figure Lengend Snippet: BNT351 suppresses viremia in HIV-1-infected humanized CD34 + NSG mice without selecting for resistant viral variants (A) Experiment scheme: HIV-1 YU2 -infected CD34 + humanized NSG mice ( n = 7/group) received subcutaneous (SC) injections of BNT351 (1 mg loading dose, followed by 0.5 mg every 3–4 days for 8 weeks) or DPBS (control) on the same days. Plasma viral loads were monitored once weekly for 17 weeks, and plasma SGS was performed at baseline and on day 84, 91, or 98. (B) RT-qPCR was used to measure plasma viral loads. HIV-1 RNA plasma copies (top) and log10 viral load changes compared with baseline (bottom) are shown. Gray shading indicates the BNT351 treatment period. Data points in white indicate viral loads below lower limit of quantification (LLOQ = 774 copies/mL). For visualization in the absolute copy number plots, viral loads

Article Snippet: Humanized CD34 + NSG female mice (NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ, JAX strain #005557) engrafted with human cord blood-derived CD34 + hematopoietic stem cells) were purchased from The Jackson Laboratory and maintained at the Decentralized Animal Husbandry Network ( Dezentrales Tierhaltungsnetzwerk ) of the University of Cologne under specific pathogen-free (SPF) conditions until the start of experiment (HIV-1 challenge), when they were moved to an S3∗∗ facility.

Techniques: Infection, Control, Clinical Proteomics, Quantitative RT-PCR, Binding Assay, Selection, Derivative Assay, Produced, Neutralization, Sequencing